Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized dose-response study of KRN321 in low- or intermediate-1-risk myelodysplastic syndrome
jRCT2080221677Phase 2
- Sponsor
- Kyowa Kirin
- Start
- Dec 2011
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of darbepoetin alfa in myelodysplastic syndrome (MDS) (2 arms), sponsored by Kyowa Kirin.
02
Drugs
darbepoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCT2080221677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221677.